Methionine aminopeptidase 2 (MetAP2) is a conserved enzyme that plays a critical role in post-translational protein modification by catalyzing the removal of initiator methionine residues from nascent polypeptides. This process is essential for protein maturation, stability, and function. MetAP2 is also implicated in regulating cellular proliferation, angiogenesis, and tumor growth, making it a potential therapeutic target in cancer and inflammatory diseases.
Antibodies targeting MetAP2 are valuable tools for studying its expression, localization, and biological functions. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to quantify MetAP2 levels in tissues or cultured cells. Research has shown that MetAP2 overexpression correlates with certain cancers, while its inhibition (e.g., via fumagillin analogs) suppresses endothelial cell growth, highlighting its role in pathological angiogenesis.
MetAP2 antibodies also aid in validating the efficacy of gene-silencing approaches (e.g., siRNA) or pharmacological inhibitors in preclinical models. Additionally, studies link MetAP2 dysfunction to metabolic disorders, broadening its relevance beyond oncology. By enabling precise detection and functional analysis, these antibodies contribute to understanding MetAP2's dual role in normal physiology and disease, supporting drug development and biomarker discovery.